SG11202110579WA - Methods of reducing large granular lymphocyte and natural killer cell levels - Google Patents

Methods of reducing large granular lymphocyte and natural killer cell levels

Info

Publication number
SG11202110579WA
SG11202110579WA SG11202110579WA SG11202110579WA SG11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA SG 11202110579W A SG11202110579W A SG 11202110579WA
Authority
SG
Singapore
Prior art keywords
methods
natural killer
killer cell
large granular
cell levels
Prior art date
Application number
SG11202110579WA
Inventor
Nenad Tomasevic
Ruo Shi Shi
Arun Kashyap
Original Assignee
Dren Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dren Bio Inc filed Critical Dren Bio Inc
Publication of SG11202110579WA publication Critical patent/SG11202110579WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/804Blood cells [leukemia, lymphoma]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202110579WA 2019-03-29 2020-03-26 Methods of reducing large granular lymphocyte and natural killer cell levels SG11202110579WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826660P 2019-03-29 2019-03-29
US202062982578P 2020-02-27 2020-02-27
PCT/US2020/025012 WO2020205440A1 (en) 2019-03-29 2020-03-26 Methods of reducing large granular lymphocyte and natural killer cell levels

Publications (1)

Publication Number Publication Date
SG11202110579WA true SG11202110579WA (en) 2021-10-28

Family

ID=72666908

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110579WA SG11202110579WA (en) 2019-03-29 2020-03-26 Methods of reducing large granular lymphocyte and natural killer cell levels

Country Status (10)

Country Link
US (1) US20220185895A1 (en)
EP (1) EP3946455A4 (en)
JP (1) JP2022528000A (en)
KR (1) KR20220032513A (en)
CN (1) CN113874035A (en)
AU (1) AU2020251987A1 (en)
CA (1) CA3135422A1 (en)
IL (1) IL286720A (en)
SG (1) SG11202110579WA (en)
WO (1) WO2020205440A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022072508A1 (en) 2020-09-30 2022-04-07 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof
CN116829185A (en) * 2020-11-18 2023-09-29 加利福尼亚大学董事会 Monoclonal antibodies against natural killer cells
WO2023183926A1 (en) * 2022-03-25 2023-09-28 Dren Bio, Inc. Anti-cd94 antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2591059C (en) * 2004-12-28 2018-11-06 Innate Pharma Monoclonal antibodies against nkg2a
US9447185B2 (en) * 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
BRPI0712953B8 (en) * 2006-06-30 2021-05-25 Novo Nordisk As anti-nkg2a antibodies, their use, and pharmaceutical composition
CN101952317B (en) * 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 Humanized anti-human NKG2A monoclonal antibody
EP2721068B1 (en) * 2011-06-17 2018-12-05 Novo Nordisk A/S Selective elimination of erosive cells
KR20170068458A (en) * 2014-09-16 2017-06-19 이나뜨 파르마, 에스.아. Treatment regimens using anti-nkg2a antibodies

Also Published As

Publication number Publication date
JP2022528000A (en) 2022-06-07
EP3946455A4 (en) 2022-12-21
IL286720A (en) 2021-10-31
US20220185895A1 (en) 2022-06-16
CN113874035A (en) 2021-12-31
KR20220032513A (en) 2022-03-15
WO2020205440A1 (en) 2020-10-08
EP3946455A1 (en) 2022-02-09
CA3135422A1 (en) 2020-10-08
AU2020251987A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
IL286720A (en) Methods of reducing large granular lymphocyte and natural killer cell levels
SG11202003201QA (en) Methods of producing modified natural killer cells and methods of use
IL285543A (en) Modified natural killer (nk) cells for immunotherapy
HK1252582A1 (en) Modified natural killer cells and natural killer cell lines having increased cytotoxicity
IL269553A (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
IL285039A (en) Compositions and methods for stimulating natural killer cells
EP3616100A4 (en) Placement and routing of cells using cell-level layout-dependent stress effects
EP3850004A4 (en) Natural killer cell compositions and immunotherapy methods for treating tumors
EP4048296A4 (en) Method of producing natural killer cells and compositions thereof
EP3686274A4 (en) Method for producing natural killer cell and use thereof
EP3580341A4 (en) Engineered natural killer (nk) cells and compositions and methods thereof
IL291622A (en) Compositions comprising regulatory t cells and methods of making and using the same
GB202001194D0 (en) Methods of cell selection and modifying cell metabolism
SG11202106565WA (en) Media and methods for differentiating natural killer cells
IL289902A (en) Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
SG11202109701SA (en) T cell receptors and methods of use thereof
SG11202101455TA (en) Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
GB201704953D0 (en) Natural killer cells
IL276374A (en) Transforming growth factor beta-resistant natural killer cells
EP3802797A4 (en) Methods of making natural killer cells and uses thereof
IL268129A (en) Compositions and methods for controlling natural killer cell activation and function
EP3790891A4 (en) Natural killer cell products and methods
IL290227A (en) T cell receptors and methods of use thereof
EP4065691A4 (en) Natural killer cell immunotherapy for the treatment of glioblastoma and other cancers
SG11202109588RA (en) T cell receptors and methods of use thereof